Biomatter raises $18M Series A to accelerate AI-driven enzyme development
Biomatter, a custom enzyme design company, raised $18 million in an oversubscribed Series A led by Astanor, with participation from existing investors including UVC Partners, to speed up AI-based enzyme development.
Read the full story at Tech.eu ↗
Timeline · 1 report
- 2026-11-12 08:51 · Tech.eu
Biomatter lands $18M to speed up enzyme development with AI